CALML3-AS1 recruits EZH2 to inhibit BTNL9 expression, where high BTNL9 expression suppresses NSCLC cell proliferation and migration, potentially through the induction of apoptosis (129). This evidence concerns the gene EZH2 and non-small cell lung carcinoma.